Skip to main content

Advertisement

SpringerLink
Log in

Paradoxical skin lesions induced by anti-TNF-α agents in SAPHO syndrome

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The objectives of the study were to characterize the clinical picture of paradoxical skin lesions in SAPHO patients treated with anti-TNF-α agents and to explore its pathogenesis. Patients treated with anti-TNF-α therapy were identified from a cohort of 164 SAPHO patients. The clinical data and skin biopsies were collected. The usage, efficacy, and side effects of anti-TNF-α therapy were recorded. Forty-one (25.0%) patients received anti-TNF-α therapy, of which seven (17.1%) developed paradoxical skin lesions after 1 to 14 infusions. Patients with such lesions were older at onset of skin lesions than those without (p = 0.034). Expression of TNF-α in palmoplantar pustulosis increased after anti-TNF-α therapy in the two examined patients with exacerbated skin lesions. Anti-TNF-α therapy induces paradoxical skin lesions in 17.1% SAPHO patients. Late onset of skin manifestations is associated with an increased risk of such lesions. The paradoxical elevation of TNF-α expression in lesions may contribute to this phenomenon.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chamot A, Benhamou C, Kahn M, Beraneck L, Kaplan G, Prost A (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Revue du rhumatisme et des maladies ostéo-articulaires 54(3):187–196

    CAS  PubMed  Google Scholar 

  2. Assmann G, Kueck O, Kirchhoff T, Rosenthal H, Voswinkel J, Pfreundschuh M, Zeidler H, Wagner AD (2009) Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study. Arthritis Res Ther 11(5):R140

    Article  Google Scholar 

  3. Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A (2004) SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 43(5):658–661. https://doi.org/10.1093/rheumatology/keh149

    Article  CAS  Google Scholar 

  4. Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffman O, Kahn MF, Meyer O (1999) SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 29(3):159–171

    Article  CAS  Google Scholar 

  5. Rozin AP (2009) SAPHO syndrome: is a range of pathogen-associated rheumatic diseases extended. Arthritis Res Ther 11(6):131

    Article  Google Scholar 

  6. Ben Abdelghani K, Dran DG, Gottenberg JE, Morel J, Sibilia J, Combe B (2010) Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 37(8):1699–1704. https://doi.org/10.3899/jrheum.091086

    Article  CAS  PubMed  Google Scholar 

  7. Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino L, Lapadula G, Lionetti P, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Girolomoni G (2014) The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 27(1 Suppl):1–10. https://doi.org/10.1177/03946320140270S101

    Article  CAS  Google Scholar 

  8. Massara A, Cavazzini P, Trotta F (2006) In SAPHO syndrome anti-TNF-α therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 45(6):730–733

    Article  CAS  Google Scholar 

  9. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M (2007) Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156(3):486–491. https://doi.org/10.1111/j.1365-2133.2007.07682.x

    Article  CAS  PubMed  Google Scholar 

  10. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL (2005) Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 7(3):R666–R676. https://doi.org/10.1186/ar1724

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Li C, Zuo Y, Wu N, Li L, Li F, Zhang W, Xu W, Zhao X, Jing H, Pan Q, Zhou W, Shi X, Fan Y, Wang J, Liu S, Liu Z, Zhang F, Zeng X, Chen H, Zhang S, Liu J, Qiu G, Wu Z, Dong Z, Zhang W (2016) Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a single centre study of a cohort of 164 patients. Rheumatology (Oxford) 55(6):1023–1030. https://doi.org/10.1093/rheumatology/kew015

    Article  CAS  Google Scholar 

  12. Kahn M-F, Khan MA (1994) The SAPHO syndrome. Baillière’s Clin Rheum 8(2):333–362. https://doi.org/10.1016/s0950-3579(94)80022-7

    Article  CAS  Google Scholar 

  13. Azim HA Jr, Peccatori FA, Brohee S et al (2015) RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 17(1):24. https://doi.org/10.1186/s13058-015-0538-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H (2007) Psoriasiform and pustular eruption induced by infliximab. J Dermatol 34(7):468–472. https://doi.org/10.1111/j.1346-8138.2007.00312.x

    Article  PubMed  Google Scholar 

  15. Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L (2013) Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis 7(10):769–779. https://doi.org/10.1016/j.crohns.2013.01.009

    Article  PubMed  Google Scholar 

  16. Collamer AN, Battafarano DF (2010) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 40(3):233–240. https://doi.org/10.1016/j.semarthrit.2010.04.003

    Article  CAS  PubMed  Google Scholar 

  17. Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63(4):567–577

    Article  CAS  Google Scholar 

  18. Ko JM, Gottlieb AB, Kerbleski JF (2009) Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 20(2):100–108. https://doi.org/10.1080/09546630802441234

    Article  CAS  Google Scholar 

  19. Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, Linos E, Liao W, Haemel A (2017) Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol 76(2):334–341. https://doi.org/10.1016/j.jaad.2016.08.012

    Article  CAS  PubMed  Google Scholar 

  20. Laga AC, Vleugels RA, Qureshi AA, Velazquez EF (2010) Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol 32(6):568–573. https://doi.org/10.1097/DAD.0b013e3181cb3ff7

    Article  PubMed  Google Scholar 

  21. Guerra I, Pérez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, Chaparro M, Mañosa M, Hinojosa E, Minguez M, Ortiz de Zarate J, Márquez L, Prieto V, García-Sánchez V, Guardiola J, Rodriguez GE, Martín-Arranz MD, García-Tercero I, Sicilia B, Masedo Á, Lorente R, Rivero M, Fernández-Salazar L, Gutiérrez A, van Domselaar M, López-SanRomán A, Ber Y, García-Sepulcre M, Ramos L, Bermejo F, Gisbert JP, Spanish GETECCU group (ENEIDA project) (2016) Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 22(4):894–901

    Article  Google Scholar 

  22. Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taieb A (2009) Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 161(5):1081–1088. https://doi.org/10.1111/j.1365-2133.2009.09329.x

    Article  CAS  PubMed  Google Scholar 

  23. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67(12):1670–1677. https://doi.org/10.1136/ard.2007.077974

    Article  CAS  PubMed  Google Scholar 

  24. Friedrich M, Tillack C, Wollenberg A, Schauber J, Brand S (2014) IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn’s disease. Inflamm Bowel Dis 20(11):1891–1901

    Article  Google Scholar 

  25. Johnston A, Fritz Y, Dawes SM, Diaconu D, al-Attar PM, Guzman AM, Chen CS, Fu W, Gudjonsson JE, McCormick TS, Ward NL (2013) Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol 190(5):2252–2262. https://doi.org/10.4049/jimmunol.1201505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Campa M, Ryan C, Menter A (2015) An overview of developing TNF-alpha targeted therapy for the treatment of psoriasis. Expert Opin Investig Drugs 24(10):1343–1354. https://doi.org/10.1517/13543784.2015.1076793

    Article  CAS  PubMed  Google Scholar 

  27. Grinblat B, Scheinberg M (2008) The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 37(4):251–255

    Article  Google Scholar 

  28. Charles P, Elliott MJ, Davis D et al (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163(3):1521–1528

    CAS  PubMed  Google Scholar 

  29. Lis K, Kuzawinska O, Balkowiec-Iskra E (2014) Tumor necrosis factor inhibitors—state of knowledge. Arch Med Sci 10(6):1175–1185. https://doi.org/10.5114/aoms.2014.47827

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pallagi-Kunstar E, Farkas K, Szepes Z et al (2014) Utility of serum TNF-alpha, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 20(17):5031–5035. https://doi.org/10.3748/wjg.v20.i17.5031

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Edrees AF, Misra SN, Abdou NI (2005) Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 23(4):469–474

    CAS  PubMed  Google Scholar 

  32. Alonso S, Tejon P, Sarasqueta C, Coto P, Alperi M, Queiro R (2016) Age at disease onset may help to further characterize the disease phenotype in psoriatic arthritis. Joint Bone Spine 83(5):533–537. https://doi.org/10.1016/j.jbspin.2015.09.004

    Article  CAS  PubMed  Google Scholar 

  33. Queiro R, Tejon P, Alonso S, Coto P (2014) Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology (Oxford, England) 53(7):1178–1185. https://doi.org/10.1093/rheumatology/ket363

    Article  CAS  Google Scholar 

  34. Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13(3):450–456

    Article  CAS  Google Scholar 

  35. Queiro R, Alonso S, Alperi M, Fernandez M, Sarasqueta C (2011) Stratification by age of onset with 30 years as age limit is an effective means of identifying PSORS1-associated psoriasis in patients with psoriatic arthritis. Joint Bone Spine 78(6):581–583. https://doi.org/10.1016/j.jbspin.2011.02.009

    Article  PubMed  Google Scholar 

  36. Cabaleiro T, Prieto-Perez R, Navarro R et al (2016) Paradoxical psoriasiform reactions to anti-TNFalpha drugs are associated with genetic polymorphisms in patients with psoriasis. Pharmacogenomics J 16(4):336–340. https://doi.org/10.1038/tpj.2015.53

    Article  CAS  PubMed  Google Scholar 

  37. Bergboer JG, Oostveen AM, de Jager ME et al (2012) Paediatric-onset psoriasis is associated with ERAP1 and IL23R loci, LCE3C_LCE3B deletion and HLA-C*06. Br J Dermatol 167(4):922–925. https://doi.org/10.1111/j.1365-2133.2012.10992.x

    Article  CAS  PubMed  Google Scholar 

  38. Prieto-Perez R, Solano-Lopez G, Cabaleiro T et al (2015) Polymorphisms associated with age at onset in patients with moderate-to-severe plaque psoriasis. J Immunol Res 2015:101879. https://doi.org/10.1155/2015/101879

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Nguyen MT, Borchers A, Selmi C, Naguwa SM, Cheema G, Gershwin ME (2012) The SAPHO syndrome. Semin Arthritis Rheum 42(3):254–265. https://doi.org/10.1016/j.semarthrit.2012.05.006

    Article  Google Scholar 

Download references

Funding

This study was supported by China National Natural Science Funds (No. 81371731) and the Capital Medical Research and Development Fund (No. 2016-4-40112), the Education Reform Projects of Peking Union Medical College (No. 2016zlgc0106), the CAMS Initiative for Innovative Medicine (No. 2017-I2M-3-001), and the National Key Research and Development Program of China (No. 2016YFC0901500).

Author information

Author notes

  1. Chen Li, Xia Wu and Yihan Cao contributed equally to this work.

Authors and Affiliations

  1. Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuai Fu Yuan, Beijing, 100730, China

    Chen Li

  2. Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuai Fu Yuan, Beijing, 100730, China

    Xia Wu, Yihan Cao, Yueping Zeng, Shuo Zhang, Yuehua Liu, Hongzhong Jin & Li Li

  3. Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuai Fu Yuan, Beijing, 100730, China

    Weihong Zhang

  4. Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuai Fu Yuan, Beijing, 100730, China

    Wen Zhang

Authors
  1. Chen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xia Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yihan Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yueping Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weihong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuehua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hongzhong Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Li.

Ethics declarations

The study was approved by the Ethics Committee of Peking Union Medical College Hospital, Peking Union Medical College, and Chinese Academy of Medical Sciences (ethics documents number ZS-944). All individual participants provided written informed consent to participate in this cohort at the time of inclusion.

Disclosures

None.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, C., Wu, X., Cao, Y. et al. Paradoxical skin lesions induced by anti-TNF-α agents in SAPHO syndrome. Clin Rheumatol 38, 53–61 (2019). https://doi.org/10.1007/s10067-018-4083-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4083-5

Keywords

Search

Navigation